Knee Innovation for the Ankle: Biointegrative Nails for Persistent Tibial Edema

 

Subchondral insufficiency (SI) of the knee manifests as pain, with imaging showing edema in the femur or tibia. SI represents bone failure beneath cartilage in early tomoderate osteoarthritis, and current surgical options are limited short of joint replacement. A February 2025 study introduces a novel structural solution adapted from construction engineering: a "rafter" arrangement of biointegrative, fiber-reinforced nails designed to internally support the failing bone.

 

Rafter-inspired structural support for subchondral bone

 

Cannulated biointegrative nails are implanted in a deliberate rafter pattern within the tibial plateau or femoral condyle, designed to stabilize subchondral bone while integrating biologically and avoiding permanent hardware.

 

Significant clinical improvements with no reoperations or implant failures at one year

 

At 12 months, nine patients showed clinically meaningful improvements across all major outcome scores — KOOS, IKDC, and PROMIS — with 87–100% of patients meeting minimal clinically important difference thresholds. There were no reoperations or implant failures, and all patients returned to sport. 

 

In the ankle: distal tibia edema

 

Persistent edema after injury or associated with tibial-sided OCD of the ankle is challenging to treat. Biointegrative nails to provide support may be the tool we have been waiting for. 

​

​

Total Ankle Arthroplasty (TAA) v. Ankle Arthrodesis (AA) Lower Reoperations and Costs at Two Years

by Vince Vacketta, DPM

 

A national database study published last month compared outcomes between two surgical treatments for end-stage ankle arthritis: primary TAA and AA. The analysis included 69,627 propensity-matched patients in each group.

 

The study found that TAA was associated with better outcomes and lower healthcare costs compared with arthrodesis: 

 

• Reoperations, Revisions, and Reoperations: The overall reoperation rate was 3.1% after TAA compared with 7.7% after arthrodesis. Revision procedures (1.1% vs. 3.3%) and early complications were also less common after TAA (1.0% vs. 2.3%) were also less common after TAA.

• Cost: Initial cost was slightly higher for TAA, though overall healthcare expenditures during the first two years were lower. Average cumulative costs at two years were $7,225 after TAA compared with $8,043 after arthrodesis.

 

Takeaway

 

Contrary to the traditional perception that fusion is the more durable option, this study found that appropriately selected patients undergoing TAA had better short-term outcomes, including fewer complications and lower two-year costs, than those receiving ankle arthrodesis.

​

Concentrated Bone Marrow Aspirate (CBMA) for Osteochondral Talus Lesions: Promising but Inconclusive

 

We all want an effective approach to improve outcomes with osteochondral lesions of the talus. CBMA, rich in stem cells and cartilage-promoting factors, has emerged as a potential solution, but clinical evidence remains limited.

 

A systematic review of 15 studies (PubMed, Scopus, Cochrane) examining functional and pain outcomes after CBMA-assisted surgical treatment of osteochondral talus lesions in adults. 

 

CBMA improved pain and function across multiple applications – standalone, with debridement, and alongside repair techniques – but results were inconsistent, and cartilage imaging scores were mixed.

 

Evidence falls short

 

CBMA shows promise as an adjunct treatment, but the current evidence doesn’t support the mic drop moment that allows us to promote it as a primary strategy.